The Christian Journal Subscribe
Published: October 29, 2021

Congress made crucial change to vaccine definition weeks before COVID-19

By

Fri Oct 29, 2021 – 11:16 pm EDTFri Oct 29, 2021 – 11:23 pm EDT ANALYSIS

(LifeSiteNews) – Without a quiet change to federal law just before the onset of COVID-19, the experimental, mRNA COVID jabs may never have been labelled as vaccines. 

A previous article on LifeSiteNews.com described the major conflicts of interest observable during the process leading up to the U.S federal government’s emergency use authorization of COVID-19 mRNA vaccines. In December 2019 (before reported outbreak of COVID-19), the U.S. federal government signed a contract with one COVID-19 vaccine maker, Moderna, which “stated ‘mRNA coronavirus vaccine candidates [are] developed and jointly owned” by both Moderna and the U.S. federal government, the article explains.   

This article discusses the additional significant fact that, also in December of 2019, the U.S. federal government changed the definition of “biological product” in federal laws governing vaccine labeling, emergency use authorization, and approval. The U.S. federal government labels vaccines as “biological products.”

A thorough discussion of the significance of the change of the U.S. federal law cannot be provided here due to the technical, scientific, and pharmaceutical terminology and descriptions required. A basic summary is as follows: without the December 2019 change to U.S. law defining “biological product,” the mRNA COVID-19 vaccines may have been required to be labeled as something other than a vaccine.   

Stated

The remainder of this article is available in its entirety at LifeSite News

The views expressed in this news alert by the author do not directly represent that of The Christian Journal or its editors


Share this Article

Download the Mobile App.
Exit mobile version